Species of sphingolipids have been associated with prediabetes risk. Dr Samuel Dagogo-Jack (University of Tennessee Health Science Center, Memphis, TN, USA) discusses the outcome of a longitudinal study conducted at the University of Tennessee which followed a diverse cohort of patients who initially presented with ‘normal’ glucose metabolism but bifurcated into two subgroups: those with ‘normal’ glucose levels (‘non-progressors’) and those who have progressed to prediabetes (‘progressors’).
The abstract ‘Association of Ceramide and Sphingolipid Species with Incident Prediabetes among Offspring of Parents with Type 2 Diabetes’ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:
- Your study determined the association between sphingolipids and prediabetes risk – please can you outline the study design and key findings? (0:41)
- Why was it important to include a diverse cohort of patients? (10:14)
Disclosures: Samuel Dagogo-Jack has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
